TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9767545

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (trandolapril) + calcium antagonist (verapamil)
Number of subjects: 37

Group type: COMPARATOR
Intervention: ACE inhibitor (trandolapril)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Calcium antagonist (verapamil)
Number of subjects: 37
Study: 8162670

Group type: EXPERIMENTAL
Intervention: Disulfiram (500 mg orally)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 20
Study: 3492487

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 100 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole 960 mg
Number of subjects: 75
Study: 30172098

Group type: EXPERIMENTAL
Intervention: Initial invasive strategy (cardiac catheterization and optimal revascularization plus optimal medical therapy)
Number of subjects: 777

Group type: COMPARATOR
Intervention: Conservative strategy (optimal medical therapy alone)
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Initial invasive strategy
Number of subjects: 777
Study: 26558626

Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3, 0.45, or 0.6 mg) administered as a single intravenous bolus 30 min before the end of surgery
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3, 0.45, or 0.6 mg)
Number of subjects: 50
Study: 24149923

Group type: EXPERIMENTAL
Intervention: TVT‐O (inside‐out transobturator tape)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: TVT‐S (tension-free vaginal tape SECUR)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both groups (TVT‐O and TVT‐S)
Number of subjects: 94
Study: 22198793

Group type: COMPARATOR
Intervention: Decolonization of the index case alone (index group)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Decolonization of all household members (household group)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Household group compared to index group
Number of subjects: 183
Study: 20478446

Group type: EXPERIMENTAL
Intervention: Combination labial plus lingual infiltration of 4% articaine with 1:100,000 epinephrine
Number of subjects: 82

Group type: COMPARATOR
Intervention: Labial infiltration of 4% articaine with 1:100,000 epinephrine
Number of subjects: 82
Study: 18328410

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-fat (0.1%) milk
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-fat (0.1%) milk with added glucose
Number of subjects: 8

Group type: COMPARATOR
Intervention: Plain water
Number of subjects: 8
Study: 17666672

Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy (girls)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy (boys)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Creative play
Number of subjects: 314

Group type: COMPARATOR
Intervention: Wait-control group
Number of subjects: 314
Study: 15015143

Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: White wine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Nonalcoholic beverage (control)
Number of subjects: 13
Study: 11128913

Group type: EXPERIMENTAL
Intervention: ABM/P-15 grafts
Number of subjects: 33

Group type: COMPARATOR
Intervention: ABM
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ABM/P-15
Number of subjects: 33
Study: 9054788

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study: 7691911

Group type: EXPERIMENTAL
Intervention: Theophylline (low concentration: 3.9 +/- 1.0 mg/liter)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Theophylline (medium concentration: 8.2 +/- 1.8 mg/liter)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Theophylline (high concentration: 13.2 +/- 2.3 mg/liter)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 3101537

Group type: EXPERIMENTAL
Intervention: Ro 15-1788 (0.6-1.0 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31519270

Group type: EXPERIMENTAL
Intervention: Active management forms of meditation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive distraction meditation
Number of subjects: 0
Study: 28423234

Group type: EXPERIMENTAL
Intervention: PVI with RDN
Number of subjects: 76

Group type: COMPARATOR
Intervention: PVI-only
Number of subjects: 76
Study: 25854014

Group type: EXPERIMENTAL
Intervention: Comprehensive group (acupuncture based on ziwuliuzhu + prozac)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Ziwuliuzhu group (acupuncture based on ziwuliuzhu)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Prozac group (oral administration of prozac)
Number of subjects: 93
Study: 22608267

Group type: EXPERIMENTAL
Intervention: Social gain-frame message
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Physical loss-frame message
Number of subjects: 108

Group type: COMPARATOR
Intervention: Social loss-frame message
Number of subjects: 108

Group type: COMPARATOR
Intervention: Physical gain-frame message
Number of subjects: 108
Study: 21042828

Group type: EXPERIMENTAL
Intervention: Clarithromycin 200 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study: 19272581

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM) course
Number of subjects: 43

Group type: COMPARATOR
Intervention: Progressive muscle relaxation (PMR) course
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both MM and PMR
Number of subjects: 43
Study: 16731542

Group type: EXPERIMENTAL
Intervention: Fixed appliances subsequent to rapid maxillary expansion (RME) and facemask therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (untreated subjects)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Class I controls
Number of subjects: 29
Study: 15318541

Group type: EXPERIMENTAL
Intervention: Dexamethasone used in the introduction of anaesthesia
Number of subjects: 361
Study: 11258645

Group type: EXPERIMENTAL
Intervention: Oral creatine supplements (4 x 5 g per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9290397

Group type: EXPERIMENTAL
Intervention: Cuff occlusion (30 seconds, 1.5, 2.5, 3.5, 4.5, and 8 minutes)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) doses (10, 20, 50, 100, 200, and 400 micrograms)
Number of subjects: 6
Study: 8322582

Group type: EXPERIMENTAL
Intervention: Naproxen 0.5 g daily + Paracetamol 4 g daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Naproxen 1.0 g daily + Paracetamol 4 g daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Naproxen 1.5 g daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Naproxen 0.5 g daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Naproxen 1.0 g daily
Number of subjects: 18
Study: 2426830

Group type: EXPERIMENTAL
Intervention: Diltiazem infusion (0.5 to 2.0 mcg/kg/min i.v.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no diltiazem)
Number of subjects: 40
Study: 31655513

Group type: EXPERIMENTAL
Intervention: LMA CTrach
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LMA Fastrach
Number of subjects: 60

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 60
Study: 28097630

Group type: EXPERIMENTAL
Intervention: Increased social support at 12-months
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: Demographic and need variables
Number of subjects: 991
Study: 26123343

Group type: EXPERIMENTAL
Intervention: Endoscopic insertion of a biliary stent
Number of subjects: 43
Study: 24004766

Group type: EXPERIMENTAL
Intervention: Treadmill desk with exercise counseling and accelerometer feedback for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treadmill desk (control period)
Number of subjects: 20
Study: 22310410

Group type: EXPERIMENTAL
Intervention: Anterior approach
Number of subjects: 36

Group type: COMPARATOR
Intervention: Posterior approach
Number of subjects: 36
Study: 19901841

Group type: EXPERIMENTAL
Intervention: Structured physician information program and feedback system (IG)
Number of subjects: 19254

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 19254
Study: 17932996

Group type: EXPERIMENTAL
Intervention: Risk-based multifactorial fall prevention programme (intervention group, IG)
Number of subjects: 591

Group type: COMPARATOR
Intervention: One-time counselling group (control group, CG)
Number of subjects: 591
Study: 16044037

Group type: EXPERIMENTAL
Intervention: Evidence-based treatment principles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systematic review process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Research designs in dental practice
Number of subjects: 0
Study: 11955536

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) administered intravenously at weeks 0, 2, and 6
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 70
Study: 9536943

Group type: EXPERIMENTAL
Intervention: Mesalazine suppositories (Pentasa) 1 g three times a week
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Mesalazine suppositories (Pentasa) 1 g/day for relapse
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 95
Study: 8585370

Group type: EXPERIMENTAL
Intervention: Pulsed high frequency electric field
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Continuous current
Number of subjects: 120

Group type: COMPARATOR
Intervention: Imitation of therapy
Number of subjects: 120
Study: 2693026

Group type: EXPERIMENTAL
Intervention: R1 (50 mg/d, p. o; total dose: 18.25 g/yr/case)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: R2 (20 mg/d, p. o; total dose: 3.6 g/6mos/case)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (riboflavin 50 mg/d, p. o.)
Number of subjects: 89
Study: 558950

Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ, 12.5 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Amobarbital (100 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31113242

Group type: EXPERIMENTAL
Intervention: In-situ group fixed with suture button technique
Number of subjects: 12

Group type: COMPARATOR
Intervention: Malreduced group rigidly held with a 3.5-mm screw
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diagnostic arthroscopy by 3 fellowship-trained foot and ankle orthopaedic surgeons
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diagnostic arthroscopy measurements
Number of subjects: 12
Study: 31045231

Group type: EXPERIMENTAL
Intervention: Active HD‐tDCS
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham HD‐tDCS
Number of subjects: 36
Study: 28825853

Group type: EXPERIMENTAL
Intervention: Non-platinum-based chemotherapy (NPBC) followed by platinum-based chemotherapy (PBC) at subsequent relapse (experimental arm)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Standard reverse treatment sequence (control arm)
Number of subjects: 215
Study: 25456793

Group type: EXPERIMENTAL
Intervention: Low-technology assisted reproduction
Number of subjects: 378
Study: 23545667

Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine (ABC/3TC)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine (TDF/FTC)
Number of subjects: 109
Study: 21464406

Group type: EXPERIMENTAL
Intervention: FOLFOX4 plus PTK/ZK
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: FOLFOX4 plus PTK/ZK (in patients with high serum LDH)
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Placebo (in patients with high serum LDH)
Number of subjects: 1168
Study: 18511076

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (Healthy Controls)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Overall (All Antidepressants)
Number of subjects: 21
Study: 16670691

Group type: EXPERIMENTAL
Intervention: B6 -50 (50 mg vitamin B6 daily for 14 days)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: B6 -100 (100 mg vitamin B6 daily for 14 days)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (no vitamin B6 supplementation, n = 20)
Number of subjects: 51
Study: 15178989

Group type: EXPERIMENTAL
Intervention: Stent-Supported Percutaneous Angioplasty
Number of subjects: 670

Group type: COMPARATOR
Intervention: Endarterectomy
Number of subjects: 670
Study: 11383780

Group type: EXPERIMENTAL
Intervention: Celsior
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control
Number of subjects: 131
Study: 9737359

Group type: EXPERIMENTAL
Intervention: Antithyroid drug plus thyroxine for 18 months
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Subtotal thyroidectomy
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Iodine-131
Number of subjects: 174

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 174

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 174
Study: 8043708

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 27
Study: 2498658

Group type: EXPERIMENTAL
Intervention: Theophylline (10 mg per kilogram of body weight per day), administered orally for two months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo, administered for two months
Number of subjects: 60
Study: 4974510

Group type: EXPERIMENTAL
Intervention: Sulphamethoxazole plus one-fifth its weight of trimethoprim (Septrin)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Sulphamethoxazole plus one-tenth its weight of trimethoprim
Number of subjects: 111

Group type: COMPARATOR
Intervention: Sulphamethoxazole alone
Number of subjects: 111
Study: 31748948

Group type: EXPERIMENTAL
Intervention: Conventional farming practices in wolfberry production
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Electricity consumption for irrigation
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nitrogen (N) fertilizer application
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Overall GWP in wolfberry planting system
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nonrenewable energy use
Number of subjects: 52
Study: 29654929

Group type: EXPERIMENTAL
Intervention: Community health workers (CHWs) assisting patients with hypertension, using video narratives from patients who have controlled their BP through diet, exercise, and medication adherence. Participants met with CHWs 5 times (twice in person and three times telephonically).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed intervention (DI) group, receiving the intervention 4 to 6 months later.
Number of subjects: 0
Study: 27172803

Group type: EXPERIMENTAL
Intervention: Type 1 model (3D model without parenchyma)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Type 2 model (3D model with transparent parenchyma)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Type 3 model (3D model with segmental partitions)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Traditional Anatomic Atlas (TAA)
Number of subjects: 92
Study: 24295218

Group type: EXPERIMENTAL
Intervention: Self-instruction video (SIV)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Traditional face-to-face (FTF)
Number of subjects: 45
Study: 22420423

Group type: EXPERIMENTAL
Intervention: Doxorubicin monotherapy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Mitomycin combined with 5-fluorouracil
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Epirubicin monotherapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: ATM levels in resistant tumors harboring TP53 or CHEK2 mutations
Number of subjects: 71
Study: 20216467

Group type: EXPERIMENTAL
Intervention: Carbohydrate (25 g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Protein (25 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (noncaloric)
Number of subjects: 10
Study: 17496307

Group type: EXPERIMENTAL
Intervention: Natural Killer (NK) cell count
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: aaIPI 3
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: NK cell count
Number of subjects: 140
Study: 15774702

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (treadmill walking at 70% peak oxygen consumption, 400 kcal)
Number of subjects: 25
Study: 12417603

Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Spleen preservation
Number of subjects: 500
Study: 7552531

Group type: EXPERIMENTAL
Intervention: Lateral groin incision (Group A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Direct incision over the femoral vessels (Group B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Patients with lymphatic obstruction (n = 8)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Patients with no lymphatic lesions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Patients with lymphatic obstruction
Number of subjects: 24
Study: 2248076

Group type: EXPERIMENTAL
Intervention: Moclobemide (100‐350 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tranylcypromine (10‐30 mg daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tranylcypromine
Number of subjects: 40
Study: 6775209

Group type: EXPERIMENTAL
Intervention: Aminophylline (350 mg per tablet, 2 tablets)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mixture (75 mg theophylline, 112.5 mg diprophylline, 112.5 mg proxyphylline per tablet, 2 tablets)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mixture
Number of subjects: 12
Study: 6871070

Group type: EXPERIMENTAL
Intervention: Regular coffee (8 cups/day for 4 weeks, 504 mg caffeine)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Decaffeinated coffee (8 cups/day for 4 weeks)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Regular coffee (8 cups/day for 4 weeks)
Number of subjects: 8
Study: 31114694

Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 196

Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 196

Group type: COMPARATOR
Intervention: lixisenatide
Number of subjects: 196
Study: 29866129

Group type: EXPERIMENTAL
Intervention: 1 g fat (Calogen®) per kg body weight orally
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 26
Study: 26751791

Group type: EXPERIMENTAL
Intervention: Epidural dexmedetomidine (3 ml loading dose at 0.5 μg kg(‐1) and continuous 80 μg in 150 ml levobupivacaine at 3 ml h(‐1) for two days)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Epidural morphine (3 ml loading dose at 0.03 mg kg(‐1) and continuous 4.5 mg in 150 ml levobupivacaine at 3 ml h(‐1) for two days)
Number of subjects: 74
Study: 23976770

Group type: EXPERIMENTAL
Intervention: Variable regimen (up to every 8 hours aspirations)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control (every 4 hours aspirations)
Number of subjects: 357
Study: 22274317

Group type: EXPERIMENTAL
Intervention: Family history (FH) recorded in case notes
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Family history recorded as not significant
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Insufficient family history records
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Significant family history meeting criteria for specialist genetics referral
Number of subjects: 114
Study: 19179905

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N-telopeptide (marker of bone resorption)
Number of subjects: 0
Study: 17597633

Group type: EXPERIMENTAL
Intervention: Obese children with OSA
Number of subjects: 52

Group type: COMPARATOR
Intervention: Normal-weight children with OSA
Number of subjects: 52
Study: 16310685

Group type: EXPERIMENTAL
Intervention: Original polypropylene mesh
Number of subjects: 184

Group type: COMPARATOR
Intervention: Resterilized polypropylene mesh
Number of subjects: 184
Study: 12215131

Group type: EXPERIMENTAL
Intervention: Surgery (open carpal tunnel release)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Splinting (wrist splinting during the night for at least 6 weeks)
Number of subjects: 176
Study: 10325486

Group type: EXPERIMENTAL
Intervention: 0.1% adapalene gel
Number of subjects: 25

Group type: COMPARATOR
Intervention: 0.05% tretinoin gel
Number of subjects: 25
Study: 7782114

Group type: COMPARATOR
Intervention: Pentamidine aerosol (300 mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Pentamidine aerosol + Roxithromycin (300 mg t.i.d.)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Roxithromycin (300 mg t.i.d.)
Number of subjects: 52
Study: 2031796

Group type: EXPERIMENTAL
Intervention: iopromide 300 (Ultravist)
Number of subjects: 446

Group type: COMPARATOR
Intervention: iohexol 300 (Omnipaque)
Number of subjects: 446
Study: 6781659

Group type: EXPERIMENTAL
Intervention: Photochemotherapy maintenance treatment once a week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Photochemotherapy maintenance treatment once every three weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ingram dithranol regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: No maintenance treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent clearing courses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular maintenance treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: No regular maintenance treatment
Number of subjects: 0
Study: 29660107

Group type: EXPERIMENTAL
Intervention: Learning landscape (LL)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Curriculum intervention
Number of subjects: 6

Group type: COMPARATOR
Intervention: Non-learning landscape (non-LL)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No curriculum intervention
Number of subjects: 6
Study: 27940571

Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT) plus Treatment as Usual (TAU)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 94